23. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787. [Epub ahead of print] PubMed PMID: 32251768; PubMed Central PMCID: PMC7129059.
24. Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment? J Am Acad Dermatol. 2020. pii: S0190-9622(20)30557-0. doi: 10.1016/j.jaad.2020.04.017. [Epub ahead of print] PubMed PMID: 32283237; PubMed Central PMCID: PMC7146719.
25. Schwartz RA, Al-Qubati Y, Zieleniewski L, Shah R, Kapila R: Onchoceriasis (river blindness): larva-induced eczema (onchodermatitis) from an important oculocutaneous tropical disease spilling over into North America and Europe. Int J Dermatol. 2019 Sep 12. doi: 10.1111/ijd.14614. [Epub ahead of print] PMID: 31513297.
26. Schwartz RA, Suskind RM. Azithromycin and COVID-19 Prompt Early Use at First Signs of this Infection in Adults and Children: An Approach Worthy of Consideration. Dermatol Ther. 2020 Jun 8:e13785. doi: 10.1111/dth.13785. Online ahead of print. PMID: 32510734
27. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2022;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. PubMed PMID: 32171062; PubMed Central PMCID: PMC7118626.
28. Amici C, Di Coro A, Ciucci A, Chiappa L, Castilletti C, Martella V, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11(8):1021-30.
29. Sodhi M, Etminan M. Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacother J Hum Pharmacol Drug Ther. 2020. doi: 10.1002/ phar.2395. [Epub ahead of print] PubMed PMID: 32267566.
30. The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID-19) pneumonia - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Apr 25]. Available from: https://clinicaltrials.gov/ct2/ show/NCT04273529.
31. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Pública. 2020;44:e40. doi: 10.26633/ RPSP.2020.40. eCollection 2020. PubMed PMID: 32256547; PubMed Central PMCID: PMC7105280.
32. Almutairi N, Schwartz RA. COVID-19 with Dermatologic Manifestations and Implications: An Unfolding Conundrum. Dermatol Ther 2020 May 9:e13544. doi:10.1111/dth.13544. Online ahead of print. PMID: 32385869
24. Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment? J Am Acad Dermatol. 2020. pii: S0190-9622(20)30557-0. doi: 10.1016/j.jaad.2020.04.017. [Epub ahead of print] PubMed PMID: 32283237; PubMed Central PMCID: PMC7146719.
25. Schwartz RA, Al-Qubati Y, Zieleniewski L, Shah R, Kapila R: Onchoceriasis (river blindness): larva-induced eczema (onchodermatitis) from an important oculocutaneous tropical disease spilling over into North America and Europe. Int J Dermatol. 2019 Sep 12. doi: 10.1111/ijd.14614. [Epub ahead of print] PMID: 31513297.
26. Schwartz RA, Suskind RM. Azithromycin and COVID-19 Prompt Early Use at First Signs of this Infection in Adults and Children: An Approach Worthy of Consideration. Dermatol Ther. 2020 Jun 8:e13785. doi: 10.1111/dth.13785. Online ahead of print. PMID: 32510734
27. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2022;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. PubMed PMID: 32171062; PubMed Central PMCID: PMC7118626.
28. Amici C, Di Coro A, Ciucci A, Chiappa L, Castilletti C, Martella V, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11(8):1021-30.
29. Sodhi M, Etminan M. Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacother J Hum Pharmacol Drug Ther. 2020. doi: 10.1002/ phar.2395. [Epub ahead of print] PubMed PMID: 32267566.
30. The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID-19) pneumonia - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Apr 25]. Available from: https://clinicaltrials.gov/ct2/ show/NCT04273529.
31. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Pública. 2020;44:e40. doi: 10.26633/ RPSP.2020.40. eCollection 2020. PubMed PMID: 32256547; PubMed Central PMCID: PMC7105280.
32. Almutairi N, Schwartz RA. COVID-19 with Dermatologic Manifestations and Implications: An Unfolding Conundrum. Dermatol Ther 2020 May 9:e13544. doi:10.1111/dth.13544. Online ahead of print. PMID: 32385869
AUTHOR CORRESPONDENCE
Mohamad Goldust MD mohamad.goldust@usb.ch
